Quick Takeaways
- Commodore Capital LP filed SCHEDULE 13G for Amylyx Pharmaceuticals, Inc. Common Stock, $0.0001 par value per share (AMLX).
- Disclosed ownership: 5.1%.
- Date of event: 10 Nov 2025.
Commodore Capital LP - 10 Nov 2025 SCHEDULE 13G Report for Amylyx Pharmaceuticals, Inc. Common Stock, $0.0001 par value per share (AMLX)
- Filing Manager
- Commodore Capital LP
- Reporting Manager
- Commodore Capital LP
- Symbol
- AMLX
- Shares outstanding
- 110,784,314 shares
- Disclosed Ownership
- 5,650,000 shares
- Ownership
- 5.1%
- Form type
- SCHEDULE 13G
- Filing time
- 17 Nov 2025, 17:39:36 UTC
- Date of event
- 10 Nov 2025
- SEC
- View on sec.gov
Quoteable Key Fact
"Commodore Capital LP disclosed 5.1% ownership in Amylyx Pharmaceuticals, Inc. Common Stock, $0.0001 par value per share (AMLX) on 10 Nov 2025."
What Changed
- No earlier schedule filing is available for direct comparison.
- Current filing was accepted on 17 Nov 2025, 17:39.
Why This Matters
- This page explains what this Schedule 13D/13G filing tells you before manager-level rows.
- You can verify ownership claims directly against the original SEC filing.
Source Evidence
Backed by Schedule 13D/13G
See Original Filing
Beneficial ownership values are sourced from the original SEC Schedule 13D/13G filing.
Reporting Managers (4)
| Name | Ownership | Shares Owned | sole voting power | shared voting power | Signature | Title | CIK |
|---|---|---|---|---|---|---|---|
| Commodore Capital LP | 5.1% | 5,650,000 | 0 | 5,650,000 | Michael Kramarz | Managing Partner | |
| Commodore Capital Master LP | 5.1% | 5,650,000 | 0 | 5,650,000 | Michael Kramarz | Authorized Signatory | |
| Robert Egen Atkinson | 5.1% | 5,650,000 | 0 | 5,650,000 | Robert Egen Atkinson | Authorized Signatory | |
| Michael Kramarz | 5.1% | 5,650,000 | 0 | 5,650,000 | Michael Kramarz | Authorized Signatory |